Short Bowel Syndrome Pipeline Featuring 18+ Companies Expected to Change the Pace of the Short Bowel Syndrome Treatment

"The Short bowel syndrome is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, or birth defects. Some children are born with an abnormally short small intestine or with part of their bowel missing, which can cause short bowel syndrome"

The drug is described in detail in the Short Bowel Syndrome pipeline report, along with its mechanism of action, Short Bowel Syndrome clinical trials, Short Bowel Syndrome NDA approvals (if any), and product development activities that include technology, Short Bowel Syndrome collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related information.

DelveInsight's, "Short Bowel Syndrome Pipeline Insight, 2023," report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the Short Bowel Syndrome pipeline drug profiles, including Short Bowel Syndrome clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Short Bowel Syndrome Pipeline Report

• The Short Bowel Syndrome pipeline report from DelveInsight shows a healthy market with 18+ Companies actively working on 18+ pipeline therapies for the Short Bowel Syndrome treatment.

• The leading Short Bowel Syndrome Companies include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, Shire, Takeda, and others.

• Promising Short Bowel Syndrome Pipeline Therapies include Teduglutide, Syringe, Apraglutide, and others.

• The Short Bowel Syndrome Companies and academics are working to assess challenges and seek opportunities that could influence in Short Bowel Syndrome R&D. The Short Bowel Syndrome pipeline therapies under development are focused on novel approaches to treat/improve in Short Bowel Syndrome.
Request a sample and discover the recent advances in Short Bowel Syndrome Drug Treatment @ Short Bowel Syndrome Pipeline Report- https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short Bowel Syndrome Overview
Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure. In rare cases, infants are born with a short bowel (congenital short bowel syndrome).

Recent Developmental Activities in the Short Bowel Syndrome Treatment Landscape

• In April 2021, 9 Meters Biopharma entered into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).

Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Short Bowel Syndrome Pipeline Report @ Latest Short Bowel Syndrome Drugs Launch- https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short Bowel Syndrome Emerging Drugs Profile

• Glepaglutide: Zealand Pharma
Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome.

Short Bowel Syndrome Pipeline Therapeutics Assessment
There are approx. 18+ key companies which are developing the therapies for Short Bowel Syndrome. The companies which have their Short Bowel Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma.

Learn more about the emerging Short Bowel Syndrome pipeline therapies @ Short Bowel Syndrome Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Short Bowel Syndrome Pipeline Report

• Coverage- Global

• Short Bowel Syndrome Companies- VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, Shire, Takeda, and others.

• Short Bowel Syndrome Pipeline Therapies- Teduglutide, Syringe, Apraglutide, and others.

• Short Bowel Syndrome Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Short Bowel Syndrome Market Drivers and Short Bowel Syndrome Market Barriers, click here @ Short Bowel Syndrome Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Short Bowel Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Short Bowel Syndrome - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Glepaglutide: Zealand Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. HM 15912: Hanmi Pharmaceutical
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Vurolenatide: 9 Meters Biopharma
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. SEFA-6179: NorthSea Therapeutics
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. GLP2-ELP: PhaseBio Pharmaceuticals
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Short Bowel Syndrome Key Companies
24. Short Bowel Syndrome Key Products
25. Short Bowel Syndrome- Unmet Needs
26. Short Bowel Syndrome- Market Drivers and Barriers
27. Short Bowel Syndrome- Future Perspectives and Conclusion
28. Short Bowel Syndrome Analyst Views
29. Short Bowel Syndrome Key Companies
30. Appendix

Got Queries? Find out the related information on Short Bowel Syndrome Mergers and acquisitions, Short Bowel Syndrome Licensing Activities @ Short Bowel Syndrome Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.